See more : Emergence Global Enterprises Inc. (EMRG.CN) Income Statement Analysis – Financial Results
Complete financial analysis of Medicure Inc. (MCUJF) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Medicure Inc., a leading company in the Drug Manufacturers – Specialty & Generic industry within the Healthcare sector.
You may be interested
- PPG Industries, Inc. (0KEI.L) Income Statement Analysis – Financial Results
- Zhejiang Yongjin Metal Technology Co., Ltd (603995.SS) Income Statement Analysis – Financial Results
- BactiQuant A/S (BACTIQ.CO) Income Statement Analysis – Financial Results
- Contrel Technology Co., Ltd. (8064.TWO) Income Statement Analysis – Financial Results
- Clarke Inc. (CKI.TO) Income Statement Analysis – Financial Results
Medicure Inc. (MCUJF)
Industry: Drug Manufacturers - Specialty & Generic
Sector: Healthcare
Website: https://www.medicure.com
About Medicure Inc.
Medicure Inc., a biopharmaceutical company, engages in the research, development, and commercialization of human therapies for the cardiovascular market in Canada and the United States. The company markets and distributes AGGRASTAT injection, a glycoprotein GP IIb/IIIa receptor antagonist for the treatment of acute coronary syndrome, including unstable angina and non-Q-wave myocardial infarction. It also offers ZYPITAMAG to treat patients with primary hyperlipidemia or mixed dyslipidemia. In addition, the company offers ReDS, a non-invasive medical device that offers measurement of lung fluid for the management of congestive heart failure. Further, the company offers Sodium Nitroprusside injection for the reduction of blood pressure for adult and pediatric patients in hypertensive crisis, as well as for producing controlled hypotension to reduce bleeding during surgery, and for the treatment of acute congestive heart failure. It offers products through retail pharmacies, as well as online. The company was incorporated in 1997 and is headquartered in Winnipeg, Canada.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 | 2005 | 2004 | 2003 | 2002 | 2001 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 21.69M | 23.07M | 21.74M | 11.61M | 20.17M | 29.11M | 27.13M | 37.78M | 22.08M | 5.05M | 2.60M | 4.80M | 3.63M | 3.32M | 4.79M | 2.25M | 5.94M | 299.74K | 459.20K | 445.46K | 241.28K | 183.91K | 135.87K |
| Cost of Revenue | 7.71M | 6.99M | 9.03M | 6.48M | 7.27M | 4.15M | 3.46M | 9.77M | 2.26M | 868.12K | 665.90K | 1.07M | 673.52K | 571.69K | 377.08K | 605.62K | 387.80K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | 13.99M | 16.08M | 12.71M | 5.13M | 12.90M | 24.96M | 23.67M | 28.01M | 19.82M | 4.18M | 1.94M | 3.73M | 2.95M | 2.75M | 4.42M | 1.64M | 5.56M | 299.74K | 459.20K | 445.46K | 241.28K | 183.91K | 135.87K |
| Gross Profit Ratio | 64.48% | 69.69% | 58.46% | 44.19% | 63.95% | 85.74% | 87.23% | 74.14% | 89.77% | 82.81% | 74.42% | 77.71% | 81.44% | 82.77% | 92.13% | 73.05% | 93.48% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% |
| Research & Development | 2.41M | 2.75M | 1.80M | 3.30M | 4.35M | 6.68M | 5.15M | 5.09M | 4.87M | 688.67K | 1.70M | 1.04M | 204.69K | 393.39K | 22.71K | 28.66M | 23.34M | 10.22M | 13.56M | 4.28M | 3.12M | 3.05M | 2.48M |
| General & Administrative | 4.13M | 4.19M | 2.70M | 4.58M | 3.40M | 19.50M | 3.35M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Selling & Marketing | 8.31M | 7.94M | 10.31M | 5.36M | 13.40M | 15.58M | 11.52M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 12.44M | 12.13M | 13.01M | 9.94M | 16.79M | 19.50M | 14.87M | 16.23M | 10.24M | 3.33M | 2.32M | 2.67M | 2.82M | 4.47M | 9.26M | 12.07M | 11.05M | 2.86M | 2.26M | 2.11M | 1.28M | 949.57K | 879.91K |
| Other Expenses | -854.00K | 346.00K | 1.83M | 0.00 | -3.62M | -1.47M | 82.49K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 898.93K | 612.52K | 372.80K | 2.65M | 2.29M | 107.38K | 57.87K | 41.01K | 33.13K | 60.51K | 12.58K |
| Operating Expenses | 13.99M | 14.88M | 14.81M | 13.24M | 21.14M | 26.18M | 20.02M | 21.33M | 15.10M | 4.02M | 4.02M | 3.72M | 3.92M | 5.48M | 9.65M | 43.39M | 36.67M | 13.18M | 15.88M | 6.43M | 4.43M | 4.06M | 3.37M |
| Cost & Expenses | 22.55M | 21.87M | 23.84M | 19.72M | 28.42M | 30.34M | 23.48M | 31.10M | 17.36M | 4.89M | 4.69M | 4.79M | 4.60M | 6.05M | 10.03M | 43.99M | 37.06M | 13.18M | 15.88M | 6.43M | 4.43M | 4.06M | 3.37M |
| Interest Income | 75.00K | 10.00K | 78.00K | 43.00K | 886.00K | 1.11M | 0.00 | 0.00 | 0.00 | 41.00 | 152.00 | 775.00 | 473.00 | 4.91K | 255.71K | 1.15M | 1.59M | 299.74K | 459.20K | 445.46K | 241.28K | 183.91K | 183.91K |
| Interest Expense | 10.00K | 0.00 | 38.00K | 49.00K | 22.00K | 53.68K | 90.00K | 208.64K | 367.27K | 415.84K | 418.07K | 553.73K | 3.12M | 3.28M | 4.94M | 3.83M | 1.96M | 400.87K | 1.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Depreciation & Amortization | 2.17M | 2.06M | 3.15M | 2.77M | 1.92M | 299.18K | 97.79K | 1.43M | 690.93K | 561.27K | 536.98K | 877.55K | 898.93K | 919.21K | 938.73K | 2.98M | 2.50M | 107.38K | 57.87K | 41.01K | 33.13K | 60.51K | 17.45K |
| EBITDA | 1.29M | 2.87M | 2.42M | -4.02M | -8.81M | -927.00K | 10.35M | 6.39M | 5.41M | 1.86M | -957.03K | -1.49M | -67.62K | -2.29M | -1.33M | -4.30M | -38.76M | -28.62M | -12.78M | -15.43M | -5.95M | -4.16M | -3.81M |
| EBITDA Ratio | 5.96% | 14.59% | 11.82% | -38.88% | -43.65% | -4.60% | 43.63% | 17.98% | 7.34% | -12.35% | -62.33% | 18.50% | -1.86% | -69.15% | -18.88% | -1,147.53% | -477.65% | -4,196.11% | -3,345.27% | -1,335.26% | -1,724.36% | -2,074.13% | -2,365.94% |
| Operating Income | -854.00K | 1.31M | -574.00K | -7.29M | -10.73M | -1.23M | 3.65M | 6.68M | 4.72M | 164.42K | -2.09M | 10.09K | -1.25M | -3.50M | -6.99M | -41.74M | -31.12M | -12.89M | -15.42M | -5.99M | -4.19M | -3.88M | -3.23M |
| Operating Income Ratio | -3.94% | 5.68% | -2.64% | -62.76% | -53.18% | -4.21% | 13.46% | 17.69% | 21.38% | 3.26% | -80.17% | 0.21% | -34.38% | -105.66% | -145.88% | -1,857.66% | -523.41% | -4,298.81% | -3,357.87% | -1,344.47% | -1,738.09% | -2,107.03% | -2,378.79% |
| Total Other Income/Expenses | -43.00K | 192.00K | -185.00K | 1.70M | -11.40M | 6.05M | -1.22M | -2.89M | -3.43M | 1.89M | 152.42K | -487.79K | 23.38M | -1.01M | -2.03M | 6.99M | 10.41M | 18.03M | -200.44K | -1.00 | 0.00 | 0.00 | 0.00 |
| Income Before Tax | -897.00K | 1.39M | -759.00K | -6.85M | -19.64M | 4.82M | 2.44M | 28.46M | 1.29M | -1.64M | -2.57M | 23.39M | -2.01M | -2.26M | -8.63M | -54.72M | -31.34M | -13.09M | -15.42M | 0.00 | 0.00 | 0.00 | 0.00 |
| Income Before Tax Ratio | -4.13% | 6.00% | -3.49% | -58.96% | -97.36% | 16.57% | 8.98% | 75.33% | 5.84% | -32.45% | -98.91% | 487.53% | -55.51% | -68.07% | -180.01% | -2,435.16% | -527.12% | -4,365.68% | -3,357.87% | 0.00% | 0.00% | 0.00% | 0.00% |
| Income Tax Expense | 25.00K | 20.00K | -32.00K | 49.00K | 145.00K | 896.88K | -9.06M | 802.83K | -379.00K | 38.20K | -3.01K | -23.93M | -2.07M | -959.99K | 6.53M | 24.81M | -1.15M | -478.47K | -553.34K | 0.00 | 0.00 | 0.00 | 0.00 |
| Net Income | -922.00K | 1.37M | -727.00K | -6.89M | -19.79M | 3.93M | 43.42M | 27.66M | 1.67M | -1.64M | -2.57M | 23.39M | -2.01M | -5.53M | -13.32M | -57.40M | -31.70M | -12.61M | -14.87M | -5.99M | -4.19M | -3.88M | -3.23M |
| Net Income Ratio | -4.25% | 5.92% | -3.34% | -59.38% | -98.08% | 13.49% | 160.03% | 73.21% | 7.56% | -32.45% | -98.91% | 487.53% | -55.51% | -166.79% | -277.85% | -2,554.48% | -533.30% | -4,206.05% | -3,237.37% | -1,344.47% | -1,738.09% | -2,107.03% | -2,378.79% |
| EPS | -0.09 | 0.13 | -0.07 | -0.65 | -1.32 | 0.25 | 2.78 | 1.80 | 0.12 | -0.13 | -0.21 | 1.99 | -0.23 | -0.64 | -1.53 | -6.86 | -4.53 | -2.52 | -3.34 | -1.61 | -1.69 | -2.10 | -3.00 |
| EPS Diluted | -0.09 | 0.13 | -0.07 | -0.65 | -1.32 | 0.24 | 2.39 | 1.56 | 0.11 | -0.13 | -0.21 | 1.99 | -0.23 | -0.64 | -1.53 | -6.86 | -4.53 | -2.52 | -3.34 | -1.61 | -1.67 | -2.10 | -3.00 |
| Weighted Avg Shares Out | 10.24M | 10.25M | 10.25M | 10.69M | 15.00M | 15.79M | 15.64M | 15.00M | 13.46M | 12.20M | 12.20M | 11.75M | 8.69M | 8.69M | 8.69M | 8.37M | 6.99M | 5.01M | 4.45M | 3.72M | 2.47M | 1.85M | 1.08M |
| Weighted Avg Shares Out (Dil) | 10.44M | 10.44M | 10.25M | 10.69M | 15.00M | 16.56M | 18.14M | 17.32M | 15.77M | 12.20M | 12.20M | 11.75M | 8.69M | 8.69M | 8.69M | 8.37M | 6.99M | 5.01M | 4.45M | 3.72M | 2.50M | 1.85M | 1.08M |
Medicure Announces FDA Provides Complete Approval to Enroll Patients in Its Pivotal Phase 3 Trial for Treatment of Rare Pediatric Disease
WINNIPEG, MB / ACCESSWIRE / November 23, 2023 / Medicure Inc. ("Medicure" or the "Company") (TSXV:MPH)(OTC PINK:MCUJF), a company focused on the development and commercialization of pharmaceuticals and healthcare products for patients and prescribers in the United States market, today...
Medicure Reports Financial Results for Quarter Ended September 30, 2023
WINNIPEG, MB / ACCESSWIRE / November 21, 2023 / Medicure Inc. ("Medicure" or the "Company") (TSXV:MPH)(OTC PINK:MCUJF), a company focused on the development and commercialization of pharmaceuticals and healthcare products for patients and prescribers in the United States market, today...
Medicure Reiterates its Commitment to Providing Exceptional Access to its Branded Pitavastatin (Zypitamag) to People Living With HIV
WINNIPEG, MB / ACCESSWIRE / August 29, 2023 / Medicure Inc. ("Medicure" or the "Company") (TSXV:MPH)(OTC:MCUJF), a company focused on the development and commercialization of pharmaceuticals and healthcare products for patients and prescribers in the United States market, reaffirms its...
Medicure Inc. (MCUJF) Q2 2023 Earnings Call Transcript
Medicure Inc. (OTCPK:MCUJF) Q2 2023 Earnings Conference Call July 31, 2023 8:30 AM ET Company Participants Albert Friesen - Chief Executive Officer Haaris Uddin - Chief Financial Officer Neil Owens - President & Chief Operating Officer Conference Call Participants Kurt...
Medicure Reports Financial Results For Quarter Ended June 30, 2023
WINNIPEG, MB / ACCESSWIRE / July 28, 2023 / Medicure Inc. ("Medicure" or the "Company") (TSXV:MPH)(OTC PINK:MCUJF), a company focused on the development and commercialization of pharmaceuticals and healthcare products for patients and prescribers in the United States market, today...
Medicure to Present Financial Results on July 31, 2023 Call at 8:30 AM ET for Quarter Ended June 30, 2023
WINNIPEG, MB / ACCESSWIRE / July 24, 2023 / Medicure Inc. ("Medicure" or the "Company") (TSXV:MPH)(OTC PINK:MCUJF), a company focused on the development and commercialization of pharmaceuticals and healthcare products for patients and prescribers in the United States market, will...
Medicure To Present Financial Results on April 10, 2023 Call at 8:30 AM ET for Quarter and Year Ended December 31, 2022
WINNIPEG, MB / ACCESSWIRE / April 5, 2023 / Medicure Inc. ("Medicure" or the "Company") (TSXV:MPH)(OTC PINK:MCUJF), a company focused on the development and commercialization of pharmaceuticals and healthcare products for patients and prescribers in the United States market, will...
Medicure Inc. (MCUJF) Q3 2022 Earnings Call Transcript
Medicure Inc. (OTCPK:MCUJF) Q3 2022 Results Conference Call November 25, 2022 8:30 AM ET Company Participants Dr. Albert Friesen - CEO Dr. Neil Owens - President and COO Haaris Uddin - CFO Conference Call Participants Kurt Caramanidis - Carl M....
MEDICURE TO PRESENT FINANCIAL RESULTS ON NOVEMBER 25, 2022 CALL at 8:30 AM ET FOR QUARTER ENDED SEPTEMBER 30, 2022
WINNIPEG, MB , Nov. 17, 2022 /PRNewswire/ - Medicure Inc. ("Medicure" or the "Company") (TSXV: MPH) (OTC: MCUJF), a company focused on the development and commercialization of pharmaceuticals and healthcare products for patients and prescribers in the United States market,...
MEDICURE TO PRESENT FINANCIAL RESULTS ON AUGUST 25, 2022 CALL at 8:30 AM ET FOR QUARTER ENDED JUNE 30, 2022
WINNIPEG, MB , Aug. 17, 2022 /PRNewswire/ - Medicure Inc. ("Medicure" or the "Company") (TSXV: MPH) (OTC: MCUJF), a company focused on the development and commercialization of pharmaceuticals and healthcare products for patients and prescribers in the United States market,...
Source: https://incomestatements.info
Category: Stock Reports